The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma
Abstract
The molecular pathogenesis of natural killer/T-cell lymphoma (NKTCL) is not well understood. We conducted whole-exome sequencing and identified Janus kinase 3 (JAK3) somatic–activating mutations (A572V and A573V) in 2 of 4 patients with NKTCLs. Further validation of the prevalence of JAK3 mutations was determined by Sanger sequencing and high-resolution melt (HRM) analysis in an additional 61 cases. In total, 23 of 65 (35.4%) cases harbored JAK3 mutations. Functional characterization of the JAK3 mutations support its involvement in cytokine-independent JAK/STAT constitutive activation leading to increased cell growth. Moreover, treatment of both JAK3-mutant and wild-type NKTCL cell lines with a novel pan-JAK inhibitor, CP-690550, resulted in dose-dependent reduction of phosphorylated STAT5, reduced cell viability, and increased apoptosis. Hence, targeting the deregulated JAK/STAT pathway could be a promising therapy for patients with NKTCLs. Significance: Gene mutations causing NKTCL have not been fully identified. Through exome sequencing, we identified activating mutations of JAK3 that may play a significant role in the pathogenesis of NKTCLs. Our findings have important implications for the management of patients with NKTCLs. Cancer Discov; 2(7); 591–7. ©2012 AACR. This article is highlighted in the In This Issue feature, p. 569.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
(2006) · New England Journal of Medicine · doi:10.1056/nejmc052564 · Cited by 189
Cited by
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
JAKs and STATs in immunity, immunodeficiency, and cancer
O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927
Epstein–Barr virus-associated lymphomas
Shannon-Lowe, C., Rickinson, A. B., & Bell, A. I. (2017) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2016.0271 · Cited by 428
Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells
Küçük, C., Jiang, B., Hu, X., Zhang, W., Chan, J. K. C., Xiao, W., Lack, N., Alkan, C., Williams, J. C., Avery, K. N., et al. (2015) · Nature Communications · doi:10.1038/ncomms7025 · Cited by 393
Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma
Jiang, L., Gu, Z.-H., Yan, Z.-X., Zhao, X., Xie, Y.-Y., Zhang, Z.-G., Pan, C.-M., Hu, Y., Cai, C.-P., Dong, Y., et al. (2015) · Nature Genetics · doi:10.1038/ng.3358 · Cited by 366
Metadata
- Authors
- Koo, G. C., Tan, S. Y., Tang, T., Poon, S. L., Allen, G. E., Tan, L., Chong, S. C., Ong, W. S., Tay, K., Tao, M., Quek, R., Loong, S., Yeoh, K.-W., Yap, S. P., Lee, K. A., Lim, L. C., Tan, D., Goh, C., Cutcutache, I., Yu, W., Young Ng, C. C., Rajasegaran, V., Heng, H. L., Gan, A., Ong, C. K., Rozen, S., Tan, P., Teh, B. T., & Lim, S. T.
- Venue
- Cancer Discovery
- Published
- 2012-07-01
- Volume
- 2
- Issue
- 7
- Pages
- 591-597
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2160289258
- Cited by
- 275
- References
- 2
- FWCI
- 11.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma. https://app.cochat.ai/papers/10.1158/2159-8290.cd-12-0028
- The paper
- Koo, G. C., Tan, S. Y., Tang, T., Poon, S. L., Allen, G. E., Tan, L., Chong, S. C., Ong, W. S., Tay, K., Tao, M., Quek, R., Loong, S., Yeoh, K.-W., Yap, S. P., Lee, K. A., Lim, L. C., Tan, D., Goh, C., Cutcutache, I., . . . Lim, S. T. (2012). Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-12-0028
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.